

# JÃ,rgen Vestbo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/648643/publications.pdf>

Version: 2024-02-01

489  
papers

60,411  
citations

1606

105  
h-index

1131

230  
g-index

502  
all docs

502  
docs citations

502  
times ranked

32013  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 347-365.	2.5	7,792
2	Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2007, 356, 775-789.	13.9	2,963
3	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 557-582.	2.5	2,393
4	Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2010, 363, 1128-1138.	13.9	2,359
5	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. European Respiratory Journal, 2019, 53, 1900164.	3.1	1,223
6	A 15-Year Follow-up Study of Ventilatory Function in Adults with Asthma. New England Journal of Medicine, 1998, 339, 1194-1200.	13.9	1,120
7	Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, The, 2003, 361, 449-456.	6.3	1,120
8	Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2015, 373, 111-122.	13.9	974
9	Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respiratory Research, 2010, 11, 122.	1.4	952
10	Chronic Obstructive Pulmonary Disease Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 598-604.	2.5	898
11	Prognostic Value of Nutritional Status in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 1856-1861.	2.5	867
12	Changes in Forced Expiratory Volume in 1 Second over Time in COPD. New England Journal of Medicine, 2011, 365, 1184-1192.	13.9	811
13	Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, The, 1999, 353, 1819-1823.	6.3	756
14	Treatable traits: toward precision medicine of chronic airway diseases. European Respiratory Journal, 2016, 47, 410-419.	3.1	746
15	Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 332-338.	2.5	692
16	Indacaterolâ€“Glycopyrronium versus Salmeterolâ€“Fluticasone for COPD. New England Journal of Medicine, 2016, 374, 2222-2234.	13.9	688
17	Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype. PLoS ONE, 2012, 7, e37483.	1.1	633
18	Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). European Respiratory Journal, 2008, 31, 869-873.	3.1	591

#	ARTICLE	IF	CITATIONS
19	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>European Respiratory Journal</i> , 2017, 49, 1700214.	3.1	536
20	Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. <i>European Respiratory Journal</i> , 2002, 20, 799-805.	3.1	487
21	Body Mass, Fat-Free Body Mass, and Prognosis in Patients with Chronic Obstructive Pulmonary Disease from a Random Population Sample. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 79-83.	2.5	487
22	Developing COPD: a 25 year follow up study of the general population. <i>Thorax</i> , 2006, 61, 935-939.	2.7	480
23	C-reactive Protein As a Predictor of Prognosis in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 250-255.	2.5	456
24	Chronic obstructive pulmonary disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15076.	18.1	444
25	Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017, 49, 1600791.	3.1	438
26	Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. <i>European Respiratory Journal</i> , 2015, 46, 1308-1321.	3.1	434
27	Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. <i>Lancet</i> , The, 2018, 391, 1076-1084.	6.3	433
28	Adherence to inhaled therapy, mortality and hospital admission in COPD. <i>Thorax</i> , 2009, 64, 939-943.	2.7	404
29	Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. <i>European Respiratory Journal</i> , 2009, 34, 641-647.	3.1	387
30	Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 1817-1826.	6.3	378
31	Prediction of the Clinical Course of Chronic Obstructive Pulmonary Disease, Using the New GOLD Classification. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 975-981.	2.5	355
32	Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 1065-1072.	2.5	353
33	Single inhaler triple therapy versus inhaled corticosteroid plus long-acting $\beta_2$ -agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. <i>Lancet</i> , The, 2016, 388, 963-973.	6.3	351
34	Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 523-525.	2.5	338
35	Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 965-974.	2.5	331
36	Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2013, 107, 1376-1384.	1.3	328

#	ARTICLE	IF	CITATIONS
37	Inflammatory Biomarkers and Exacerbations in Chronic Obstructive Pulmonary Disease. JAMA - Journal of the American Medical Association, 2013, 309, 2353.	3.8	326
38	Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet, The, 2017, 389, 1919-1929.	6.3	326
39	Epidemiology of chronic obstructive pulmonary disease. European Respiratory Journal, 2001, 17, 982-994.	3.1	315
40	Informe 2017 de la Iniciativa Global para el Diagnóstico, Tratamiento y Prevención de la Enfermedad Pulmonar Obstructiva Crónica: Resumen Ejecutivo de GOLD. Archivos De Bronconeumología, 2017, 53, 128-149.	0.4	312
41	Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. Nature Genetics, 2017, 49, 426-432.	9.4	306
42	Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respiratory Medicine, the, 2013, 1, 210-223.	5.2	301
43	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report. Respirology, 2017, 22, 575-601.	1.3	299
44	Body Mass, Fat-Free Body Mass, and Prognosis in Patients with Chronic Obstructive Pulmonary Disease from a Random Population Sample: Findings from the Copenhagen City Heart Study. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 79-83.	2.5	292
45	Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respiratory Research, 2009, 10, 59.	1.4	287
46	Hospitalized Exacerbations of COPD. Chest, 2015, 147, 999-1007.	0.4	269
47	Airway Wall Thickening and Emphysema Show Independent Familial Aggregation in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 500-505.	2.5	268
48	Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. European Respiratory Journal, 2002, 20, 819-825.	3.1	266
49	Six-Minute-Walk Test in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 382-386.	2.5	257
50	Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. Nature Genetics, 2019, 51, 494-505.	9.4	257
51	Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax, 2005, 60, 992-997.	2.7	253
52	Determinants of Depression in the ECLIPSE Chronic Obstructive Pulmonary Disease Cohort. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 604-611.	2.5	250
53	Can GOLD Stage 0 Provide Information of Prognostic Value in Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 329-332.	2.5	249
54	Prevalence and Progression of Osteoporosis in Patients With COPD. Chest, 2009, 136, 1456-1465.	0.4	240

#	ARTICLE	IF	CITATIONS
55	U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. Journal of Allergy and Clinical Immunology, 2017, 139, 1797-1807.	1.5	236
56	Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. European Respiratory Journal, 2002, 20, 539-544.	3.1	224
57	COPD-related morbidity and mortality after smoking cessation: status of the evidence. European Respiratory Journal, 2008, 32, 844-853.	3.1	224
58	The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respiratory Medicine, the, 2013, 1, 129-136.	5.2	224
59	Chronic mucus hypersecretion in COPD and death from pulmonary infection. European Respiratory Journal, 1995, 8, 1333-1338.	3.1	220
60	COPD: the dangerous underestimate of 15%. Lancet, The, 2006, 367, 1216-1219.	6.3	220
61	The need for clean air: The way air pollution and climate change affect allergic rhinitis and asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2170-2184.	2.7	219
62	A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Human Molecular Genetics, 2012, 21, 947-957.	1.4	216
63	The natural history of chronic obstructive pulmonary disease. European Respiratory Journal, 2006, 27, 627-643.	3.1	212
64	Elevated Plasma Fibrinogen Associated with Reduced Pulmonary Function and Increased Risk of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1008-1011.	2.5	208
65	Inflammatory Biomarkers and Comorbidities in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 982-988.	2.5	198
66	Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease. Journal of the American Medical Directors Association, 2012, 13, 291-297.	1.2	193
67	Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 51-57.	2.5	192
68	At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1540-1551.	2.5	185
69	Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. European Respiratory Journal, 1999, 13, 1109.	3.1	184
70	Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal, 2012, 39, 38-45.	3.1	180
71	Cardiovascular events in patients with COPD: TORCH Study results. Thorax, 2010, 65, 719-725.	2.7	177
72	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Archivos De Bronconeumologia, 2017, 53, 128-149.	0.4	173

#	ARTICLE	IF	CITATIONS
73	Effectiveness of Fluticasone Furoate/Vilanterol for COPD in Clinical Practice. <i>New England Journal of Medicine</i> , 2016, 375, 1253-1260.	13.9	172
74	Determinants of poor 6-min walking distance in patients with COPD: The ECLIPSE cohort. <i>Respiratory Medicine</i> , 2010, 104, 849-857.	1.3	171
75	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, e4-e27.	2.5	166
76	Inhaled corticosteroids in COPD: friend or foe?. <i>European Respiratory Journal</i> , 2018, 52, 1801219.	3.1	166
77	Smoking Reduction, Smoking Cessation, and Mortality: A 16-year Follow-up of 19,732 Men and Women from the Copenhagen Centre for Prospective Population Studies. <i>American Journal of Epidemiology</i> , 2002, 156, 994-1001.	1.6	165
78	Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. <i>Thorax</i> , 2002, 57, 967-972.	2.7	164
79	Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. <i>European Respiratory Journal</i> , 2013, 42, 636-646.	3.1	164
80	Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. <i>Thorax</i> , 2012, 67, 701-708.	2.7	160
81	Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 317-322.	2.5	157
82	Integrated care pathways for airway diseases (AIRWAYS-ICPs). <i>European Respiratory Journal</i> , 2014, 44, 304-323.	3.1	154
83	Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. <i>European Respiratory Journal</i> , 2011, 37, 508-515.	3.1	152
84	Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. <i>Thorax</i> , 2014, 69, 718-723.	2.7	151
85	Change in Lung Function and Morbidity from Chronic Obstructive Pulmonary Disease in $\alpha_1$ -Antitrypsin MZ Heterozygotes: A Longitudinal Study of the General Population. <i>Annals of Internal Medicine</i> , 2002, 136, 270.	2.0	145
86	The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD) – why and what?. <i>Clinical Respiratory Journal</i> , 2012, 6, 208-214.	0.6	143
87	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , 2015, 45, 879-905.	3.1	138
88	Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 2037-2047.e10.	1.5	138
89	Changes in physical activity and all-cause mortality in COPD. <i>European Respiratory Journal</i> , 2014, 44, 1199-1209.	3.1	137
90	Short telomere length, lung function and chronic obstructive pulmonary disease in 46 individuals. <i>Thorax</i> , 2013, 68, 429-435.	2.7	134

#	ARTICLE	IF	CITATIONS
91	Gender differences in the management and experience of Chronic Obstructive Pulmonary Disease. <i>Respiratory Medicine</i> , 2004, 98, 1207-1213.	1.3	133
92	Association analysis identifies TLR7 and TLR8 as novel risk genes in asthma and related disorders. <i>Thorax</i> , 2008, 63, 1064-1069.	2.7	133
93	Mortality in women and men in relation to smoking. <i>International Journal of Epidemiology</i> , 1998, 27, 27-32.	0.9	132
94	Potential misclassification of causes of death from COPD. <i>European Respiratory Journal</i> , 2006, 28, 781-785.	3.1	131
95	Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD. <i>Annals of the American Thoracic Society</i> , 2015, 12, 27-34.	1.5	131
96	Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017, 50, 1602265.	3.1	131
97	Should We View Chronic Obstructive Pulmonary Disease Differently after ECLIPSE?. A Clinical Perspective from the Study Team. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 1022-1030.	2.5	130
98	Identification of Five Chronic Obstructive Pulmonary Disease Subgroups with Different Prognoses in the ECLIPSE Cohort Using Cluster Analysis. <i>Annals of the American Thoracic Society</i> , 2015, 12, 303-312.	1.5	126
99	Lessons from ECLIPSE: a review of COPD biomarkers. <i>Thorax</i> , 2014, 69, 666-672.	2.7	125
100	A Pooled Analysis of FEV 1 Decline in COPD Patients Randomized to Inhaled Corticosteroids or Placebo. <i>Chest</i> , 2007, 131, 682-689.	0.4	121
101	MUC5B Is the Major Mucin in the Gel Phase of Sputum in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 1033-1039.	2.5	120
102	Community Transmission of Oseltamivir-Resistant A(H1N1)pdm09 Influenza. <i>New England Journal of Medicine</i> , 2011, 365, 2541-2542.	13.9	119
103	Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis. <i>Lancet Respiratory Medicine</i> , 2016, 4, 454-462.	5.2	119
104	Genome-Wide Association Analysis of Blood Biomarkers in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 1238-1247.	2.5	117
105	The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. <i>Respiratory Medicine</i> , 2016, 114, 27-37.	1.3	113
106	COPD. <i>Clinics in Chest Medicine</i> , 2014, 35, 1-6.	0.8	111
107	Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 699-709.	5.2	111
108	Chronic obstructive pulmonary disease in patients admitted with heart failure. <i>Journal of Internal Medicine</i> , 2008, 264, 361-369.	2.7	106

#	ARTICLE	IF	CITATIONS
109	Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 426-434.	5.2	106
110	CD4-Regulatory Cells in COPD Patients. <i>Chest</i> , 2007, 132, 156-163.	0.4	105
111	Recommendations for epidemiological studies on COPD. <i>European Respiratory Journal</i> , 2011, 38, 1261-1277.	3.1	105
112	Association of Cardiovascular Disease With Respiratory Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2166-2177.	1.2	104
113	A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. <i>Nicotine and Tobacco Research</i> , 2004, 6, 55-61.	1.4	103
114	Inhaled corticosteroids and decline of lung function in community residents with asthma. <i>Thorax</i> , 2006, 61, 100-104.	2.7	103
115	The Many "Small COPDs". <i>Chest</i> , 2008, 134, 623-627.	0.4	102
116	Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study. <i>Lancet Respiratory Medicine</i> , 2013, 1, 543-550.	5.2	102
117	Measuring bronchodilation in COPD clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 379-384.	1.1	100
118	Resting heart rate is a predictor of mortality in COPD. <i>European Respiratory Journal</i> , 2013, 42, 341-349.	3.1	100
119	Current Controversies and Future Perspectives in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 507-513.	2.5	98
120	The prognostic importance of lung function in patients admitted with heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 685-691.	2.9	97
121	Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. <i>Thorax</i> , 2020, 75, 520-527.	2.7	97
122	Aortic Augmentation Index: Reference Values in a Large Unselected Population by Means of the SphygmoCor Device. <i>American Journal of Hypertension</i> , 2010, 23, 180-185.	1.0	95
123	Possible gene dosage effect of glutathione-S-transferases on atopic asthma: Using real-time PCR for quantification of GSTM1 and GSTT1 gene copy numbers. <i>Human Mutation</i> , 2004, 24, 208-214.	1.1	94
124	Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. <i>European Respiratory Journal</i> , 1995, 8, 1694-1698.	3.1	93
125	Inhaled Corticosteroids With/Without Long-Acting $\beta_2$ -Agonists Reduce the Risk of Rehospitalization and Death in COPD Patients. <i>Treatments in Respiratory Medicine</i> , 2003, 2, 67-74.	1.4	93
126	Impulse oscillometry in COPD: Identification of measurements related to airway obstruction, airway conductance and lung volumes. <i>Respiratory Medicine</i> , 2009, 103, 136-143.	1.3	93



#	ARTICLE	IF	CITATIONS
127	Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. <i>European Respiratory Review</i> , 2017, 26, 160073.	3.0	93
128	Sex Differences in Emphysema and Airway Disease in Smokers. <i>Chest</i> , 2009, 136, 1480-1488.	0.4	88
129	Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD. <i>Respiratory Research</i> , 2011, 12, 3.	1.4	88
130	Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. <i>Lancet, The</i> , 2017, 390, 2247-2255.	6.3	88
131	Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. <i>European Respiratory Journal</i> , 2008, 32, 17-24.	3.1	87
132	FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. <i>European Respiratory Journal</i> , 2013, 42, 1391-1401.	3.1	87
133	Chronic Obstructive Pulmonary Disease Biomarker(s) for Disease Activity Neededâ€”Urgently. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 863-864.	2.5	85
134	Smoking reduction, smoking cessation, and incidence of fatal and non-fatal myocardial infarction in Denmark 1976-1998: a pooled cohort study. <i>Journal of Epidemiology and Community Health</i> , 2003, 57, 412-416.	2.0	84
135	Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. <i>Respiratory Medicine</i> , 2014, 108, 729-736.	1.3	83
136	Reproducibility of exhaled breath condensate pH in chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , 2005, 25, 269-274.	3.1	81
137	The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. <i>European Respiratory Journal</i> , 2013, 41, 1017-1022.	3.1	81
138	Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. <i>Thorax</i> , 2015, 70, 33-40.	2.7	80
139	Changes in Alcohol Intake and Mortality. <i>Epidemiology</i> , 2004, 15, 222-228.	1.2	78
140	Bias due to withdrawal in long-term randomised trials in COPD: Evidence from the TORCH study. <i>Clinical Respiratory Journal</i> , 2011, 5, 44-49.	0.6	78
141	Is Diastolic Hypertension an Independent Risk Factor for Stroke in the Presence of Normal Systolic Blood Pressure in the Middle-aged and Elderly?. <i>American Journal of Hypertension</i> , 1997, 10, 634-639.	1.0	77
142	Î± <sub>1</sub> -Antitrypsin Protease Inhibitor MZ Heterozygosity Is Associated With Airflow Obstruction in Two Large Cohorts. <i>Chest</i> , 2010, 138, 1125-1132.	0.4	77
143	Predictors of Objective Cough Frequency in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 943-949.	2.5	77
144	Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. <i>Respiratory Medicine</i> , 2015, 109, 1138-1146.	1.3	77

#	ARTICLE	IF	CITATIONS
145	Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2014, 2, 23-34.	0.5	76
146	Social position and mortality from respiratory diseases in males and females. <i>European Respiratory Journal</i> , 2003, 21, 821-826.	3.1	75
147	Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 172, 460-464.	2.5	74
148	Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. <i>Respiratory Medicine</i> , 2009, 103, 1572-1579.	1.3	74
149	Predictors of Smoking Reduction and Cessation in a Cohort of Danish Moderate and Heavy Smokers. <i>Preventive Medicine</i> , 2001, 33, 46-52.	1.6	73
150	Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. <i>Respiratory Medicine</i> , 2004, 98, 1045-1050.	1.3	73
151	COVID-19 and COPD: a narrative review of the basic science and clinical outcomes. <i>European Respiratory Review</i> , 2020, 29, 200199.	3.0	73
152	Convergence of the epidemiology and pathology of COPD. <i>Thorax</i> , 2005, 61, 86-88.	2.7	72
153	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Review</i> , 2015, 24, 159-172.	3.0	72
154	Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-“Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 275-287.	2.5	72
155	C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. <i>Thorax</i> , 2011, 66, 197-204.	2.7	70
156	Prevalence, Characteristics, and Prognosis of Early Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 671-680.	2.5	70
157	Localization of Microfibrillar-Associated Protein 4 (MFAP4) in Human Tissues: Clinical Evaluation of Serum MFAP4 and Its Association with Various Cardiovascular Conditions. <i>PLoS ONE</i> , 2013, 8, e82243.	1.1	70
158	A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. <i>European Respiratory Journal</i> , 2009, 33, 1039-1044.	3.1	69
159	Genetic influences on chronic obstructive pulmonary disease – A twin study. <i>Respiratory Medicine</i> , 2010, 104, 1890-1895.	1.3	69
160	Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th Anniversary: a brief history of time. <i>European Respiratory Journal</i> , 2017, 50, 1700671.	3.1	69
161	The COPD Biomarker Qualification Consortium (CBQC). <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 367-377.	0.7	67
162	Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. <i>European Respiratory Journal</i> , 2016, 47, 1365-1373.	3.1	64

#	ARTICLE	IF	CITATIONS
163	Increased T-regulatory cells within lymphocyte follicles in moderate COPD. <i>European Respiratory Journal</i> , 2009, 34, 89-94.	3.1	63
164	Smoking cessation intervention in a large randomised population-based study. The Inter99 study. <i>Preventive Medicine</i> , 2005, 40, 285-292.	1.6	62
165	Biomarkers in Chronic Obstructive Pulmonary Disease. <i>Proceedings of the American Thoracic Society</i> , 2009, 6, 543-545.	3.5	62
166	Machine Learning and Prediction of All-Cause Mortality in COPD. <i>Chest</i> , 2020, 158, 952-964.	0.4	62
167	Gastroesophageal reflux disease and exacerbations in chronic obstructive pulmonary disease. <i>Respirology</i> , 2015, 20, 101-107.	1.3	61
168	Copenhagen comorbidity in HIV infection (COCOMO) study: a study protocol for a longitudinal, non-interventional assessment of non-AIDS comorbidity in HIV infection in Denmark. <i>BMC Infectious Diseases</i> , 2016, 16, 713.	1.3	61
169	Long-term Course of Depression Trajectories in Patients With COPD. <i>Chest</i> , 2016, 149, 916-926.	0.4	61
170	Peak Flow as Predictor of Overall Mortality in Asthma and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 163, 690-693.	2.5	60
171	Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. <i>Respiratory Research</i> , 2011, 12, 71.	1.4	60
172	Beta-blockers in COPD: time for reappraisal. <i>European Respiratory Journal</i> , 2016, 48, 880-888.	3.1	60
173	Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. <i>European Respiratory Journal</i> , 2018, 51, 1702146.	3.1	60
174	Natural Histories of Chronic Obstructive Pulmonary Disease. <i>Proceedings of the American Thoracic Society</i> , 2008, 5, 878-883.	3.5	59
175	Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. <i>European Respiratory Journal</i> , 2010, 35, 532-539.	3.1	59
176	It is possible to help smokers in early motivational stages to quit. The Inter99 study. <i>Preventive Medicine</i> , 2005, 40, 278-284.	1.6	58
177	Identification of a novel asthma susceptibility gene on chromosome 1qter and its functional evaluation. <i>Human Molecular Genetics</i> , 2008, 17, 1890-1903.	1.4	58
178	Factors associated with change in exacerbation frequency in COPD. <i>Respiratory Research</i> , 2013, 14, 79.	1.4	58
179	High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD – results from the ECLIPSE study. <i>Respiratory Research</i> , 2016, 17, 125.	1.4	57
180	Airflow limitation in people living with HIV and matched uninfected controls. <i>Thorax</i> , 2018, 73, 431-438.	2.7	57

#	ARTICLE	IF	CITATIONS
181	COPD Stage and Risk of Hospitalization for Infectious Disease*. Chest, 2008, 134, 46-53.	0.4	55
182	Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707 Subjects. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 35-46.	1.4	55
183	Low Use and Adherence to Maintenance Medication in Chronic Obstructive Pulmonary Disease in the General Population. Journal of General Internal Medicine, 2015, 30, 51-59.	1.3	54
184	Lung Function Trajectories Leading to Chronic Obstructive Pulmonary Disease as Predictors of Exacerbations and Mortality. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 210-218.	2.5	54
185	Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax, 2005, 60, 301-304.	2.7	53
186	COPD phenotype description using principal components analysis. Respiratory Research, 2009, 10, 41.	1.4	53
187	Tiotropium for Treatment of Stable COPD: A Meta-analysis of Clinically Relevant Outcomes. Respiratory Care, 2011, 56, 477-487.	0.8	53
188	Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum. Respiratory Research, 2014, 15, 103.	1.4	53
189	Exome Array Analysis Identifies a Common Variant in <i>IL27</i> Associated with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 48-57.	2.5	52
190	The global impact of Aspergillus infection on COPD. BMC Pulmonary Medicine, 2020, 20, 241.	0.8	52
191	A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma. Pharmacogenetics and Genomics, 2004, 14, 627-633.	5.7	51
192	Prevalence of COPD in Copenhagen. Respiratory Medicine, 2011, 105, 410-417.	1.3	51
193	Cardiovascular Morbidity in COPD: A Study of the General Population. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2011, 7, 5-10.	0.7	51
194	Inhaled corticosteroid containing combinations and mortality in COPD. European Respiratory Journal, 2018, 52, 1801230.	3.1	51
195	Changes in smoking habits and risk of asthma: a longitudinal population based study. European Respiratory Journal, 2001, 18, 549-554.	3.1	50
196	One-year change in health status and subsequent outcomes in COPD. Thorax, 2015, 70, 420-425.	2.7	50
197	Should We Continue Using Questionnaires on Breathlessness in Epidemiologic Surveys?. The American Review of Respiratory Disease, 1988, 137, 1114-1118.	2.9	49
198	Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients. Respiratory Medicine, 2010, 104, 1297-1303.	1.3	49

#	ARTICLE	IF	CITATIONS
199	Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 881-888.	2.5	49
200	Importance of Early COPD in Young Adults for Development of Clinical COPD. Findings from the Copenhagen General Population Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1245-1256.	2.5	49
201	Does Cytomegalovirus Predict a Poor Prognosis in <i>Pneumocystis carinii</i> Pneumonia Treated With Corticosteroids?. <i>Chest</i> , 1995, 108, 411-414.	0.4	48
202	Increase in prevalence and severity of asthma in young adults in Copenhagen. <i>Thorax</i> , 2000, 55, 833-836.	2.7	48
203	Use of different exhaled nitric oxide multiple flow rate models in COPD. <i>European Respiratory Journal</i> , 2007, 29, 651-659.	3.1	48
204	Management of Dyspnea and Anxiety in Chronic Obstructive Pulmonary Disease: A Critical Review. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 1096.e1-1096.e17.	1.2	48
205	Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1126-1137.	1.2	48
206	Prognostic significance of chronic respiratory symptoms in individuals with normal spirometry. <i>European Respiratory Journal</i> , 2019, 54, 1900734.	3.1	48
207	High aortic augmentation index predicts mortality and cardiovascular events in men from a general population, but not in women. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 1005-1012.	0.8	47
208	Trajectory of Preserved Ratio Impaired Spirometry: Natural History and Long-Term Prognosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 910-920.	2.5	47
209	Changes in Body Composition in Patients with Chronic Obstructive Pulmonary Disease: Do They Influence Patient-Related Outcomes?. <i>Annals of Nutrition and Metabolism</i> , 2013, 63, 239-247.	1.0	46
210	Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease. <i>Respiratory Research</i> , 2014, 15, 147.	1.4	46
211	Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 47-55.	2.5	46
212	Molecular Diagnosis of Intermediate and Severe $\alpha$ 1-Antitrypsin Deficiency: MZ Individuals with Chronic Obstructive Pulmonary Disease May Have Lower Lung Function Than MM Individuals. <i>Clinical Chemistry</i> , 2001, 47, 56-62.	1.5	45
213	Genome-wide study identifies two loci associated with lung function decline in mild to moderate COPD. <i>Human Genetics</i> , 2013, 132, 79-90.	1.8	45
214	Prevalence of night-time dyspnoea in COPD and its implications for prognosis. <i>European Respiratory Journal</i> , 2014, 43, 1590-1598.	3.1	45
215	Association of Blood Eosinophil and Blood Neutrophil Counts with Asthma Exacerbations in the Copenhagen General Population Study. <i>Clinical Chemistry</i> , 2017, 63, 823-832.	1.5	45
216	The revised GOLD 2017 COPD categorization in relation to comorbidities. <i>Respiratory Medicine</i> , 2018, 134, 79-85.	1.3	45

#	ARTICLE	IF	CITATIONS
217	Chronic bronchitis in an elderly population. <i>Age and Ageing</i> , 2003, 32, 636-642.	0.7	44
218	Improved survival prediction from lung function data in a large population sample. <i>Respiratory Medicine</i> , 2009, 103, 442-448.	1.3	44
219	Candidate genes for COPD in two large data sets. <i>European Respiratory Journal</i> , 2011, 37, 255-263.	3.1	44
220	The association between aortic augmentation index and cardiovascular risk factors in a large unselected population. <i>Journal of Human Hypertension</i> , 2012, 26, 476-484.	1.0	44
221	Microfibrillar-associated protein 4: A potential biomarker of chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2014, 108, 1336-1344.	1.3	44
222	Opportunities and Challenges in the Genetics of COPD 2010: An International COPD Genetics Conference Report. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2011, 8, 121-135.	0.7	43
223	The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma. <i>BMC Pulmonary Medicine</i> , 2015, 15, 160.	0.8	43
224	Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort. <i>European Respiratory Journal</i> , 2021, 58, 2003927.	3.1	43
225	The repeatability of interleukin-6, tumor necrosis factor- $\alpha$ , and C-reactive protein in COPD patients over one year. <i>International Journal of COPD</i> , 2009, 4, 149.	0.9	42
226	Vitamin D, vitamin D binding protein, lung function and structure in COPD. <i>Respiratory Medicine</i> , 2013, 107, 1578-1588.	1.3	42
227	Chronic Respiratory Symptoms with Normal Spirometry. A Reliable Clinical Entity?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 17-22.	2.5	42
228	ERS and tobacco harm reduction. <i>European Respiratory Journal</i> , 2019, 54, 1902009.	3.1	42
229	Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 689-698.	2.5	42
230	Alveolar Damage in AIDS-Related <i>Pneumocystis carinii</i> Pneumonia. <i>Chest</i> , 1997, 111, 1193-1199.	0.4	41
231	Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. <i>Health and Quality of Life Outcomes</i> , 2012, 10, 100.	1.0	41
232	The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2015, 16, 101.	1.4	41
233	Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. <i>Heart</i> , 2017, 103, 1536-1542.	1.2	41
234	Development, dimensions, reliability and validity of the novel Manchester COPD fatigue scale. <i>Thorax</i> , 2009, 64, 950-955.	2.7	40

#	ARTICLE	IF	CITATIONS
235	Socioeconomic Status and Prognosis of COPD in Denmark. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2014, 11, 431-437.	0.7	40
236	Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2015, 109, 1147-1154.	1.3	40
237	Natural history of <scp>COPD</scp>: Focusing on change in <scp>FEV</scp><sub>1</sub>. <i>Respirology</i> , 2016, 21, 34-43.	1.3	40
238	Validation of a Chronic Obstructive Pulmonary Disease screening questionnaire for population surveys. <i>Respiratory Medicine</i> , 2004, 98, 78-83.	1.3	39
239	Family based association analysis of the IL2 and IL15 genes in allergic disorders. <i>European Journal of Human Genetics</i> , 2006, 14, 227-235.	1.4	39
240	Overweight and Obesity May Lead to Under-diagnosis of Airflow Limitation: Findings from the Copenhagen City Heart Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015, 12, 5-13.	0.7	38
241	Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 980-989.	5.2	38
242	Microfibrillar-associated protein 4 modulates airway smooth muscle cell phenotype in experimental asthma. <i>Thorax</i> , 2015, 70, 862-872.	2.7	37
243	A systematic review of breath analysis and detection of volatile organic compounds in COPD. <i>Journal of Breath Research</i> , 2016, 10, 034002.	1.5	37
244	Acceptance of the smoking cessation intervention in a large population-based study: The Inter99 study. <i>Scandinavian Journal of Public Health</i> , 2005, 33, 138-145.	1.2	36
245	Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD. <i>BMC Pulmonary Medicine</i> , 2014, 14, 43.	0.8	36
246	Interleukin 18 receptor 1 gene polymorphisms are associated with asthma. <i>European Journal of Human Genetics</i> , 2008, 16, 1083-1090.	1.4	35
247	A comparison of COPD patients with and without ACOS in the ECLIPSE study. <i>European Respiratory Journal</i> , 2016, 47, 1559-1562.	3.1	35
248	The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 955-959.e6.	1.2	35
249	&lt;p&gt;FEV<sub>1</sub> is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease&lt;/p&gt;. <i>International Journal of COPD</i> , 2020, Volume 15, 1135-1142.	0.9	35
250	Coronary heart disease and heart failure in asthma, COPD and asthma-COPD overlap. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000470.	1.2	35
251	Characteristics of Undertreatment in COPD in the General Population. <i>Chest</i> , 2013, 144, 1811-1818.	0.4	34
252	Characterization of spontaneous air space enlargement in mice lacking microfibrillar-associated protein 4. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 308, L1114-L1124.	1.3	34

#	ARTICLE	IF	CITATIONS
253	ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations. <i>European Respiratory Journal</i> , 2022, 59, 2102006.	3.1	34
254	Long-term survival for COPD patients receiving noninvasive ventilation for acute respiratory failure. <i>International Journal of COPD</i> , 2013, 8, 215.	0.9	33
255	Young and middle-aged adults with airflow limitation according to lower limit of normal but not fixed ratio have high morbidity and poor survival: a population-based prospective cohort study. <i>European Respiratory Journal</i> , 2018, 51, 1702681.	3.1	33
256	Whole exome sequencing analysis in severe chronic obstructive pulmonary disease. <i>Human Molecular Genetics</i> , 2018, 27, 3801-3812.	1.4	32
257	Surfactant protein D is a candidate biomarker for subclinical tobacco smoke-induced lung damage. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014, 306, L887-L895.	1.3	31
258	Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. <i>International Journal of COPD</i> , 2017, Volume 12, 2917-2928.	0.9	31
259	A comparison of mortality rates in three prospective studies from Copenhagen with mortality rates in the central part of the city, and the entire country. <i>Copenhagen Center for Prospective Population Studies. European Journal of Epidemiology</i> , 1998, 14, 579-585.	2.5	30
260	Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD. <i>European Journal of Radiology</i> , 2014, 83, 2093-2101.	1.2	30
261	Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. <i>European Heart Journal</i> , 2018, 39, 3128-3134.	1.0	30
262	Multistudy Fine Mapping of Chromosome 2q Identifies XRCC5 as a Chronic Obstructive Pulmonary Disease Susceptibility Gene. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 605-613.	2.5	29
263	Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. <i>Respiratory Medicine</i> , 2016, 119, 87-95.	1.3	29
264	Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. <i>Respiratory Medicine</i> , 2017, 131, 27-34.	1.3	29
265	Prospective observational study in patients with obstructive lung disease: NOVELTY design. <i>ERJ Open Research</i> , 2019, 5, 00036-2018.	1.1	29
266	Smoking reduction and biomarkers in two longitudinal studies. <i>Addiction</i> , 2006, 101, 1516-1522.	1.7	28
267	Onset of Effect of Aclidinium, a Novel, Long-Acting Muscarinic Antagonist, in Patients with COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2010, 7, 331-336.	0.7	28
268	Using an electronic medical record (EMR) to conduct clinical trials: Salford Lung Study feasibility. <i>BMC Medical Informatics and Decision Making</i> , 2015, 15, 8.	1.5	28
269	Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability. <i>European Respiratory Journal</i> , 2018, 51, 1701531.	3.1	28
270	Long-term exposure to cement dust and later hospitalization due to respiratory disease. <i>International Archives of Occupational and Environmental Health</i> , 1990, 62, 217-220.	1.1	27



#	ARTICLE	IF	CITATIONS
271	Smoking reduction intervention in a large population-based study. The Inter99 study. <i>Preventive Medicine</i> , 2005, 40, 112-118.	1.6	27
272	A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations. <i>European Respiratory Journal</i> , 2013, 41, 12-17.	3.1	27
273	Left ventricular volume and wall stress are linked to lung function impairment in COPD. <i>International Journal of Cardiology</i> , 2018, 261, 172-178.	0.8	27
274	Cigarette smoking and response to inhaled corticosteroids in COPD. <i>European Respiratory Journal</i> , 2018, 51, 1701393.	3.1	27
275	Clinical Assessment, Staging, and Epidemiology of Chronic Obstructive Pulmonary Disease Exacerbations. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 252-256.	3.5	26
276	Management and survival of patients admitted with an exacerbation of COPD: Comparison of two Danish patient cohorts. <i>Clinical Respiratory Journal</i> , 2010, 4, 208-214.	0.6	26
277	Impact of non-linear smoking effects on the identification of gene-by-smoking interactions in COPD genetics studies. <i>Thorax</i> , 2011, 66, 903-909.	2.7	26
278	Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD. <i>European Respiratory Journal</i> , 2020, 55, 1902119.	3.1	26
279	Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. <i>European Respiratory Journal</i> , 2021, 57, 2001339.	3.1	26
280	Prognostic Value of Interleukin-8 in AIDS-associated <i>Pneumocystis carinii</i> Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995, 151, 1058-1062.	2.5	25
281	Association of PTGDR gene polymorphisms with asthma in two Caucasian populations. <i>Genes and Immunity</i> , 2007, 8, 398-403.	2.2	25
282	Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD. <i>Respiratory Medicine</i> , 2013, 107, 1722-1730.	1.3	25
283	Validation of the i-BODE Index as a Predictor of hospitalization and Mortality in Patients with COPD Participating in Pulmonary Rehabilitation. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2014, 11, 381-387.	0.7	25
284	The Effect of Fatigue and Fatigue Intensity on Exercise Tolerance in Moderate COPD. <i>Lung</i> , 2016, 194, 889-895.	1.4	25
285	Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD. <i>European Respiratory Journal</i> , 2018, 51, 1800120.	3.1	25
286	Prognosis of COPD depends on severity of exacerbation history: A population-based analysis. <i>Respiratory Medicine</i> , 2019, 155, 141-147.	1.3	25
287	Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration. <i>European Respiratory Journal</i> , 2019, 53, 1900217.	3.1	25
288	Susceptibility to Chronic Mucus Hypersecretion, a Genome Wide Association Study. <i>PLoS ONE</i> , 2014, 9, e91621.	1.1	25

#	ARTICLE	IF	CITATIONS
289	Methods for therapeutic trials in COPD: lessons from the TORCH trial. <i>European Respiratory Journal</i> , 2009, 34, 1018-1023.	3.1	24
290	Medically treated exacerbations in COPD by GOLD 1-4: A valid, robust, and seemingly low-biased definition. <i>Respiratory Medicine</i> , 2015, 109, 1562-1568.	1.3	24
291	Obstructive sleep apnea and hypertriglyceridaemia share common genetic background: Results of a twin study. <i>Journal of Sleep Research</i> , 2020, 29, e12979.	1.7	24
292	Highly significant linkage to chromosome 3q13.31 for rhinitis and related allergic diseases. <i>Journal of Medical Genetics</i> , 2005, 43, e10-e10.	1.5	23
293	A functional CD86 polymorphism associated with asthma and related allergic disorders. <i>Journal of Medical Genetics</i> , 2007, 44, 509-515.	1.5	23
294	Iron Deficiency in COPD Associates with Increased Pulmonary Artery Pressure Estimated by Echocardiography. <i>Heart Lung and Circulation</i> , 2017, 26, 101-104.	0.2	23
295	Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort. <i>Respiratory Research</i> , 2019, 20, 63.	1.4	23
296	Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2014, 108, 1647-1654.	1.3	22
297	Systematic literature review of patient-reported outcome measures used in assessment and measurement of sleep disorders in chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2015, 10, 293.	0.9	22
298	Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD. <i>Chest</i> , 2015, 148, 16-23.	0.4	22
299	β <sub>2</sub> -Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT. <i>Annals of the American Thoracic Society</i> , 2018, 15, 608-614.	1.5	22
300	Novel Anti-Inflammatory Agents in COPD: Targeting Lung and Systemic Inflammation. <i>Current Drug Targets</i> , 2013, 14, 235-245.	1.0	22
301	Significant linkage to chromosome 12q24.32-q24.33 and identification of SFRS8 as a possible asthma susceptibility gene. <i>Thorax</i> , 2006, 61, 874-879.	2.7	21
302	Exhaled nitric oxide measure using multiple flows in clinically relevant subgroups of COPD. <i>Respiratory Medicine</i> , 2011, 105, 1338-1344.	1.3	21
303	Susceptibility to exacerbation in COPD. <i>Lancet Respiratory Medicine</i> , 2017, 5, e29.	5.2	21
304	What is the impact of GOLD 2017 recommendations in primary care? – a descriptive study of patient classifications, treatment burden and costs. <i>International Journal of COPD</i> , 2018, Volume 13, 3485-3492.	0.9	21
305	Elevated blood eosinophils in acute COPD exacerbations: better short- and long-term prognosis. <i>European Clinical Respiratory Journal</i> , 2020, 7, 1757274.	0.7	21
306	Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. <i>Thorax</i> , 2005, 60, 343-349.	2.7	20

#	ARTICLE	IF	CITATIONS
307	Enzyme-Linked Immunosorbent Assay Characterization of Basal Variation and Heritability of Systemic Microfibrillar-Associated Protein 4. <i>PLoS ONE</i> , 2013, 8, e82383.	1.1	20
308	Prognostic Value of C-Reactive Protein, Leukocytes, and Vitamin D in Severe Chronic Obstructive Pulmonary Disease. <i>Scientific World Journal</i> , The, 2014, 2014, 1-7.	0.8	20
309	Chronic obstructive pulmonary disease in patients with end-stage kidney disease on hemodialysis. <i>Hemodialysis International</i> , 2016, 20, 68-77.	0.4	20
310	Prevalence of airflow obstruction in patients with stable systolic heart failure. <i>BMC Pulmonary Medicine</i> , 2017, 17, 6.	0.8	20
311	Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials. <i>ERJ Open Research</i> , 2019, 5, 00072-2019.	1.1	20
312	Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population study. <i>International Journal of COPD</i> , 2019, Volume 14, 853-861.	0.9	20
313	Relationship between supernormal lung function and long-term risk of hospitalisations and mortality: a population-based cohort study. <i>European Respiratory Journal</i> , 2021, 57, 2004055.	3.1	20
314	Supernormal lung function and risk of COPD: A contemporary population-based cohort study. <i>EClinicalMedicine</i> , 2021, 37, 100974.	3.2	20
315	Factor V Leiden Homozygosity, Dyspnea, and Reduced Pulmonary Function. <i>Archives of Internal Medicine</i> , 2005, 165, 2032.	4.3	19
316	CD8 chemokine receptors in chronic obstructive pulmonary disease. <i>Clinical and Experimental Immunology</i> , 2008, 154, 56-63.	1.1	19
317	What Is Chronic Obstructive Pulmonary Disease Anyway?. Continua, Categories, Cut Points, and Moving beyond Spirometry. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1036-1037.	2.5	19
318	Common Genetic Variants Associated with Resting Oxygenation in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014, 51, 678-687.	1.4	19
319	COPD monocytes demonstrate impaired migratory ability. <i>Respiratory Research</i> , 2017, 18, 90.	1.4	19
320	Automated oxygen control with O2matic <sup>®</sup> during admission with exacerbation of COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 3997-4003.	0.9	19
321	Changes in lung function in European adults born between 1884 and 1996 and implications for the diagnosis of lung disease: a cross-sectional analysis of ten population-based studies. <i>Lancet Respiratory Medicine</i> , 2022, 10, 83-94.	5.2	19
322	The prognostic significance of lung function in stable heart failure outpatients. <i>Clinical Cardiology</i> , 2017, 40, 1145-1151.	0.7	18
323	Biomarkers of collagen turnover are related to annual change in FEV1 in patients with chronic obstructive pulmonary disease within the ECLIPSE study. <i>BMC Pulmonary Medicine</i> , 2017, 17, 164.	0.8	18
324	Specific elastin degradation products are associated with poor outcome in the ECLIPSE COPD cohort. <i>Scientific Reports</i> , 2019, 9, 4064.	1.6	18

#	ARTICLE	IF	CITATIONS
325	Impact of diagnostic criteria on the prevalence of <sc>COPD</sc>. Clinical Respiratory Journal, 2013, 7, 297-303.	0.6	17
326	Surfactant Protein D Deficiency Aggravates Cigarette Smoke-Induced Lung Inflammation by Upregulation of Ceramide Synthesis. Frontiers in Immunology, 2018, 9, 3013.	2.2	17
327	Comparison of five major airflow limitation criteria to identify high-risk individuals with COPD: a contemporary population-based cohort. Thorax, 2020, 75, 944-954.	2.7	17
328	COVID-19 Clinical Trials: Unraveling a Methodological Gordian Knot. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 635-637.	2.5	17
329	Bronchodilator reversibility in COPD: the roguish but harmless little brother of airway hyperresponsiveness?. European Respiratory Journal, 2005, 26, 6-7.	3.1	16
330	Fibrinogen and $\alpha_1$ -antitrypsin in COPD exacerbations. Thorax, 2015, 70, 1014-1021.	2.7	16
331	Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study. Clinical Epidemiology, 2017, Volume 9, 231-243.	1.5	16
332	The severity of airways obstruction as a determinant of treatment response in COPD. International Journal of COPD, 2006, 1, 209-218.	0.9	16
333	Substantial need for early diagnosis, rehabilitation and treatment of chronic obstructive pulmonary disease. Danish Medical Journal, 2012, 59, A4396.	0.5	16
334	Are Respiratory Symptoms and Chronic Airflow Limitation Really Associated with an Increased Risk of Respiratory Cancer?. International Journal of Epidemiology, 1991, 20, 375-378.	0.9	15
335	The EXACT-Pro: Measuring Exacerbations of COPD. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 287-288.	2.5	15
336	Can patients with COPD self-manage?. Lancet, The, 2012, 380, 624-625.	6.3	15
337	Is chronic obstructive pulmonary disease associated with increased arterial stiffness?. Respiratory Medicine, 2012, 106, 397-405.	1.3	15
338	Prevention of COPD exacerbations: medications and other controversies. ERJ Open Research, 2015, 1, 00011-2015.	1.1	15
339	Computed tomography quantification of emphysema in people living with HIV and uninfected controls. European Respiratory Journal, 2018, 52, 1800296.	3.1	15
340	End-product of fibrinogen is elevated in emphysematous chronic obstructive pulmonary disease and is predictive of mortality in the ECLIPSE cohort. Respiratory Medicine, 2019, 160, 105814.	1.3	15
341	&lt;p&gt;Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk&lt;/p&gt;. International Journal of COPD, 2020, Volume 15, 543-552.	0.9	15
342	Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial. ERJ Open Research, 2021, 7, 00902-2020.	1.1	15

#	ARTICLE	IF	CITATIONS
343	A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations. <i>ERJ Open Research</i> , 2019, 5, 00136-2019.	1.1	15
344	Quantitative linkage genome scan for atopy in a large collection of Caucasian families. <i>Human Genetics</i> , 2007, 121, 83-92.	1.8	14
345	Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial. <i>Annals of Intensive Care</i> , 2016, 6, 114.	2.2	14
346	Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study. <i>International Journal of COPD</i> , 2018, Volume 13, 1125-1134.	0.9	14
347	Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study. <i>Respiratory Medicine</i> , 2018, 141, 198-206.	1.3	14
348	Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol. <i>ERJ Open Research</i> , 2020, 6, 00193-2020.	1.1	14
349	The environmental impact of inhaled therapy: making informed treatment choices. <i>European Respiratory Journal</i> , 2022, 60, 2102106.	3.1	14
350	COPD: Who Has it, Who Hasn't " and Then What ?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2007, 4, 303-304.	0.7	13
351	Endotrophin, an extracellular hormone, in combination with neopeptide markers of von Willebrand factor improves prediction of mortality in the ECLIPSE COPD cohort. <i>Respiratory Research</i> , 2020, 21, 202.	1.4	13
352	Small airway dysfunction in well-treated never-smoking HIV-infected individuals. <i>European Respiratory Journal</i> , 2017, 49, 1602186.	3.1	12
353	Stability of the frequent COPD exacerbator in the general population: A Danish nationwide register-based study. <i>Npj Primary Care Respiratory Medicine</i> , 2017, 27, 25.	1.1	12
354	Mechanisms Underlying the Association of Chronic Obstructive Pulmonary Disease With Heart Failure. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1963-1973.	2.3	12
355	The Pressing Need to Redefine "COPD". <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2019, 6, 380-383.	0.5	12
356	Another Piece of the Inhaled Corticosteroids-in-COPD Puzzle. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 514-515.	2.5	11
357	COPD: A prevalence estimation model. <i>Respirology</i> , 2005, 10, 594-602.	1.3	11
358	Improving the care of COPD patients " suggested action points by the COPD exacerbations taskforce for reducing the burden of exacerbations of COPD. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2006, 15, 139-142.	2.5	11
359	Chronic Cough and Phlegm in Young Adults. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 2-3.	2.5	11
360	Association Between Vitamin D Status and COPD Phenotypes. <i>Lung</i> , 2014, 192, 493-497.	1.4	11

#	ARTICLE	IF	CITATIONS
361	The development and first validation of the Manchester Early Morning Symptoms Index (MEMSI) for patients with COPD. <i>Thorax</i> , 2015, 70, 757-763.	2.7	11
362	The era of research collaborations: new models for working together. <i>European Respiratory Journal</i> , 2017, 49, 1601848.	3.1	11
363	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. <i>Annals of the American Thoracic Society</i> , 2019, 16, 29-39.	1.5	11
364	Outcomes Evaluated in Controlled Clinical Trials on the Management of COVID-19: A Methodological Systematic Review. <i>Life</i> , 2020, 10, 350.	1.1	11
365	International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 25-33.	2.5	11
366	Observational Studies of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: Misconstrued Immortal Time Bias. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 464a-465.	2.5	10
367	Systemic inflammation and progression of COPD. <i>Thorax</i> , 2007, 62, 469-470.	2.7	10
368	Exhaled CO, a predictor of lung function?. <i>Respiratory Medicine</i> , 2007, 101, 581-586.	1.3	10
369	A multi-center randomized, controlled, open-label trial evaluating the effects of eosinophil-guided corticosteroid-sparing therapy in hospitalised patients with COPD exacerbations â€” The CORTICO steroid reduction in COPD (CORTICO-COP) study protocol. <i>BMC Pulmonary Medicine</i> , 2017, 17, 114.	0.8	10
370	The DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials Network (DECODE-NET): rationale and vision. <i>European Respiratory Journal</i> , 2020, 56, 2000627.	3.1	10
371	Independent Association of Interleukin 6 With Low Dynamic Lung Function and Airflow Limitation in Well-Treated People With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2021, 223, 1690-1698.	1.9	10
372	Are pharmacists reducing COPDâ€™s impact through smoking cessation and assessing inhaled steroid use?. <i>Respiratory Medicine</i> , 2012, 106, 230-234.	1.3	9
373	Real-World Data and Randomised Controlled Trials: The Salford Lung Study. <i>Advances in Therapy</i> , 2020, 37, 977-997.	1.3	9
374	Fraction of Exhaled Nitric Oxide Levels Are Elevated in People Living With Human Immunodeficiency Virus Compared to Uninfected Controls, Suggesting Increased Eosinophilic Airway Inflammation. <i>Clinical Infectious Diseases</i> , 2020, 71, 3214-3221.	2.9	9
375	Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease. <i>Clinics in Chest Medicine</i> , 2020, 41, 463-474.	0.8	9
376	Prevalence and clinical implications of respiratory viruses in stable chronic obstructive pulmonary disease (COPD) and exacerbations: a systematic review and meta-analysis protocol. <i>BMJ Open</i> , 2020, 10, e035640.	0.8	9
377	Automated lung sound analysis using the LungPass platform: a sensitive and specific tool for identifying lower respiratory tract involvement in COVID-19. <i>European Respiratory Journal</i> , 2021, 58, 2101907.	3.1	9
378	Correlation Between Emphysema and Lung Function in Healthy Smokers and Smokers With COPD. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2015, 2, 204-213.	0.5	9

#	ARTICLE	IF	CITATIONS
379	Evidence for an asthma risk locus on chromosome Xp: a replication linkage study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 1235-1238.	2.7	8
380	COPD assessment: I, II, III, IV and/or A, B, C, D. <i>European Respiratory Journal</i> , 2014, 43, 949-950.	3.1	8
381	Î2-Adrenergic genotypes and risk of severe exacerbations in COPD: a prospective cohort study. <i>Thorax</i> , 2019, 74, 934-940.	2.7	8
382	Automatic oxygen titration with O2maticÂ® to patients admitted with COVID-19 and hypoxemic respiratory failure. <i>European Clinical Respiratory Journal</i> , 2020, 7, 1833695.	0.7	8
383	Pulse Wave Velocity in Chronic Obstructive Pulmonary Disease and the Impact of Inhaled Therapy (SUMMIT): A Randomized Double-Blind Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1307-1310.	2.5	8
384	Interstitial Lung Abnormalities in People With HIV Infection and Uninfected Controls. <i>Journal of Infectious Diseases</i> , 2020, 221, 1973-1977.	1.9	8
385	Exacerbation history, severity of dyspnoea and maintenance treatment predicts risk of future exacerbations in patients with COPD in the general population. <i>Respiratory Medicine</i> , 2022, 192, 106725.	1.3	8
386	Prognosis of Patients with Chronic Obstructive Pulmonary Disease Not Eligible for Major Clinical Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 271-280.	2.5	8
387	Has risk associated with smoking increased? Results from the Copenhagen Center for Prospective Population Studies. <i>International Journal of Epidemiology</i> , 1997, 26, 1214-1218.	0.9	7
388	Rapid Detection of Cytomegalovirus in Bronchoalveolar Lavage Fluid and Serum Samples by Polymerase Chain Reaction: Correlation of Virus Isolation and Clinical Outcome for Patients with Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 1997, 24, 878-883.	2.9	7
389	Seretide withdrawal increases airway inflammation in moderate COPD patients. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 1165-1166.	0.8	7
390	Circulating nitric oxide products do not solely reflect nitric oxide release in cirrhosis and portal hypertension. <i>Liver International</i> , 2011, 31, 1381-1387.	1.9	7
391	GOLD and the fixed ratio. <i>European Respiratory Journal</i> , 2011, 38, 481-482.	3.1	7
392	Independent Associations of Tumor Necrosis Factor-Alpha and Interleukin-1 Beta With Radiographic Emphysema in People Living With HIV. <i>Frontiers in Immunology</i> , 2021, 12, 668113.	2.2	7
393	Stigma: an unmet public health priority in COPD. <i>Lancet Respiratory Medicine</i> , 2021, 9, 955-956.	5.2	7
394	Fletcher and Peto 40 Years On. A Tribute and Reflection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1420-1422.	2.5	7
395	A new Cochrane review on electronic cigarettes for smoking cessation: should we change our practice?. <i>European Respiratory Journal</i> , 2020, 56, 2004083.	3.1	7
396	Reply: Correctly Defining Criteria for Diagnosing Chronic Obstructive Pulmonary Disease Matters. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 230-231.	2.5	7

#	ARTICLE	IF	CITATIONS
397	The Single-Breath Nitrogen Test, Mortality, and Cancer. <i>The American Review of Respiratory Disease</i> , 1990, 142, 1022-1025.	2.9	6
398	COPD in the ECRHS. <i>Thorax</i> , 2004, 59, 89-90.	2.7	6
399	Personality Traits and Mental Symptoms are Associated with Impact of Chronic Obstructive Pulmonary Disease on Patients' Daily Life. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 773-778.	0.7	6
400	Chronic Mucus Hypersecretion and the Natural History of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 602-603.	2.5	6
401	Triple Therapy in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1082-1083.	2.5	6
402	Incidental lung cancers and positive computed tomography images in people living with HIV. <i>Aids</i> , 2017, 31, 1973-1977.	1.0	6
403	Telemediated Training in the Home as a Part of the Everyday Life and Practice With Very Severe Chronic Obstructive Pulmonary Disease. <i>Qualitative Health Research</i> , 2020, 30, 2132-2145.	1.0	6
404	Fixed Triple Therapy in Chronic Obstructive Pulmonary Disease and Survival. Living Better, Longer, or Both?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1463-1464.	2.5	6
405	Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD. <i>European Respiratory Journal</i> , 2022, 59, 2102899.	3.1	6
406	Assessing Treatment Success or Failure as an Outcome in Randomised Clinical Trials of COPD Exacerbations. A Meta-Epidemiological Study. <i>Biomedicines</i> , 2021, 9, 1837.	1.4	6
407	Scintigraphic demonstration of the thoracic duct following oral ingestion of <sup>123</sup> I-heptadecanoic acid. <i>Gastrointestinal Radiology</i> , 1989, 14, 212-214.	0.4	5
408	Predictive value of the single-breath nitrogen test for hospitalization due to respiratory disease. <i>Lung</i> , 1990, 168, 93-101.	1.4	5
409	Chronic Obstructive Pulmonary Disease: Different Risk Factors and Different Natural Histories?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 968-970.	2.5	5
410	COPD drugs: the urgent need for innovation. <i>Lancet Respiratory Medicine</i> , the, 2014, 2, 14-15.	5.2	5
411	Absence of <i>Pneumocystis jirovecii</i> Colonization in Human Immunodeficiency Virus-Infected Individuals With and Without Airway Obstruction and With Undetectable Viral Load. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw044.	0.4	5
412	Clinical trial research in focus: time to reflect on the design of exacerbation trials in COPD. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 466-468.	5.2	5
413	The emerging Chinese COPD epidemic. <i>Lancet</i> , The, 2018, 391, 1642-1643.	6.3	5
414	Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups. <i>Respiratory Medicine</i> , 2019, 147, 58-65.	1.3	5



#	ARTICLE	IF	CITATIONS
415	World No Tobacco Day: smoking, nicotine and children. <i>European Respiratory Journal</i> , 2020, 55, 2001633.	3.1	5
416	World No Tobacco Day: what's in it for us?. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 318, L1008-L1009.	1.3	5
417	A rational approach to e-cigarettes: challenging ERS policy on tobacco harm reduction. <i>European Respiratory Journal</i> , 2020, 55, 2000355.	3.1	5
418	Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials. <i>Respiratory Research</i> , 2021, 22, 155.	1.4	5
419	Small-airways dysfunction in never smoking asbestos exposed Danish plumbers. <i>International Archives of Occupational and Environmental Health</i> , 1990, 62, 209-212.	1.1	4
420	Statistical analysis of COPD exacerbations. <i>European Respiratory Journal</i> , 2008, 32, 1421-1422.	3.1	4
421	Lung function decline in COPD trials. <i>European Respiratory Journal</i> , 2009, 33, 708-709.	3.1	4
422	Hypothesis: in COPD, a pound of cure may be better than an ounce of prevention. <i>Thorax</i> , 2011, 66, 643-645.	2.7	4
423	A Novel Study Design for the Comparison Between Once-Daily QVA149 and Twice-Daily Salmeterol/Fluticasone on the Reduction of COPD Exacerbations: The FLAME Study. <i>Chest</i> , 2014, 145, 408A.	0.4	4
424	Changes in GOLD: today and tomorrow. <i>Lancet Respiratory Medicine</i> , 2015, 3, 424-426.	5.2	4
425	Effectiveness of Fluticasone Furoate/Vilanterol in COPD. <i>New England Journal of Medicine</i> , 2016, 375, 2605-2607.	13.9	4
426	Long-Acting $\beta_2$ -Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1641-1644.	2.5	4
427	Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients. <i>ERJ Open Research</i> , 2019, 5, 00021-2019.	1.1	4
428	Impact of pre-enrolment medication use on clinical outcomes in SUMMIT. <i>ERJ Open Research</i> , 2019, 5, 00203-2018.	1.1	4
429	Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design. <i>ERJ Open Research</i> , 2020, 6, 00044-2020.	1.1	4
430	Impact of self-reported environmental mould exposure on COPD outcomes. <i>Pulmonology</i> , 2023, 29, 375-384.	1.0	4
431	Psychometric Properties of the COPD-Specific Beliefs About Medicine Questionnaire in an Outpatient Population: A Rasch-Analysis. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2016, 3, 748-757.	0.5	4
432	Inhaled glucocorticoids in COPD: immortal time bias. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 127.	2.5	4

#	ARTICLE	IF	CITATIONS
433	To Use or Not to Use. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 284-285.	2.5	3
434	Natural experiments and large databases in respiratory and cardiovascular disease. European Respiratory Review, 2016, 25, 130-134.	3.0	3
435	Decade of the lung—a call for action to promote lung health globally. Lancet Respiratory Medicine, 2016, 4, e3-e4.	5.2	3
436	The European Respiratory Society evaluates its 2013–2018 strategic plan implementation. European Respiratory Journal, 2016, 47, 693-698.	3.1	3
437	Exhaled breath condensate in chronic obstructive pulmonary disease: methodological challenges and clinical application. Minerva Respiratory Medicine, 2018, 57, .	0.1	3
438	Was the implementation strategy of the ProACT trial adequately proactive?. Breathe, 2019, 15, 77-80.	0.6	3
439	Combining biomarkers of clot resolution and alveolar basement membrane destruction predicts mortality in the ECLIPSE COPD cohort. Respiratory Medicine, 2020, 173, 106185.	1.3	3
440	Adrenal suppression in patients with chronic obstructive pulmonary disease treated with glucocorticoids: Role of specific glucocorticoid receptor polymorphisms. PLoS ONE, 2022, 17, e0262898.	1.1	3
441	COPD, diagrams and traditions: time to move on?. Thorax, 2008, 63, 755-756.	2.7	2
442	Letter to the editors. Thorax, 2013, 68, 387.1-388.	2.7	2
443	Chronic bronchitis: so much more than just a smoker's cough. International Journal of Tuberculosis and Lung Disease, 2014, 18, 760-760.	0.6	2
444	COPD. , 2016, , 751-766.e7.		2
445	The Manchester Respiratory-related Sleep Symptoms scale for patients with COPD: development and validation. International Journal of COPD, 2018, Volume 13, 3885-3894.	0.9	2
446	Inhaled triple therapy in chronic obstructive pulmonary disease – Authors' reply. Lancet, The, 2018, 392, 1113-1114.	6.3	2
447	Validation of lung density indices by cardiac CT for quantification of lung emphysema. International Journal of COPD, 2018, Volume 13, 3321-3330.	0.9	2
448	Accuracy of Airflow Obstruction Thresholds for Predicting COPD-Related Hospitalization and Mortality. JAMA - Journal of the American Medical Association, 2019, 321, 2412.	3.8	2
449	Regional differences in rate of FEV1 decline in COPD: lessons from SUMMIT. European Respiratory Journal, 2019, 53, 1900278.	3.1	2
450	Outcomes consequent to ‘early’ COPD for interventional studies. European Respiratory Journal, 2020, 55, 2000073.	3.1	2

#	ARTICLE	IF	CITATIONS
451	Impact of socioeconomic status on participation and outcomes in the Salford Lung Studies. ERJ Open Research, 2020, 6, 00193-2019.	1.1	2
452	Increased serum SP-D in identification of high-risk smokers at high risk of COPD. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L1005-L1010.	1.3	2
453	Should e-cigarettes be licensed as medicines?. BMJ, The, 2022, 376, n2912.	3.0	2
454	Another public health catastrophe. Lancet, The, 2021, 398, 2243.	6.3	2
455	Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials, 2022, 23, 307.	0.7	2
456	Potential clinical implications of targeted spirometry for detection of COPD: A contemporary population-based cohort study. Respiratory Medicine, 2022, 197, 106852.	1.3	2
457	NICE and GOLD response. Lancet Respiratory Medicine, the, 2013, 1, 442.	5.2	1
458	Hospitalised for Chronic Obstructive Pulmonary Disease: On a Dangerous Route. Respiration, 2013, 85, 11-12.	1.2	1
459	S51 Circulating Desmosine Relates To Cardiovascular Comorbidity, Coronary Artery Calcification Score (cacs), Systemic Inflammation And Mortality In Patients With Copd. Thorax, 2014, 69, A28-A29.	2.7	1
460	Paper acceptance time in respiratory research: room for improvement?. European Respiratory Journal, 2017, 49, 1601951.	3.1	1
461	Taken to task: what is and is not an appropriate response to an ERS guidelines task force?. European Respiratory Journal, 2017, 50, 1700952.	3.1	1
462	RISK OF DEATH AND COPD HOSPITALIZATION WITH FLUTICASONE FLUROATE-CONTAINING THERAPY: POST HOC SUBGROUP ANALYSIS FROM THE SUMMIT TRIAL IN PATIENTS WITH COPD AND A HISTORY OF EXACERBATION. Chest, 2020, 158, A1755-A1760.	0.4	1
463	Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial. Respiratory Research, 2020, 21, 263.	1.4	1
464	Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus. Journal of Infectious Diseases, 2021, 223, 94-100.	1.9	1
465	Safety data in randomised real-world evidence studies: Salford Lung Study learnings. ERJ Open Research, 2021, 7, 00966-2020.	1.1	1
466	Management of chronic obstructive pulmonary disease. British Journal of Hospital Medicine (London,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.2	1
467	Re-assessing the importance of FEV <sub>1</sub> decline. , 0, , 134-142.		1
468	Clinical Assessment of COPD. , 2011, , 21-31.		1

#	ARTICLE	IF	CITATIONS
469	Reorganisation of acute referral to an emergency department resulted in fewer admissions for chronic obstructive pulmonary disease but in higher rates of non-invasive ventilation. Danish Medical Journal, 2014, 61, A4958.	0.5	1
470	Outpatient management of chronic obstructive pulmonary disease. Clinical Medicine, 2004, 4, 220-224.	0.8	0
471	Choice of medications when treating stable COPD. Clinical Respiratory Journal, 2010, 4, 195-196.	0.6	0
472	Republished editorial: Hypothesis: in COPD, a pound of cure may be better than an ounce of prevention. Postgraduate Medical Journal, 2011, 87, 793-794.	0.9	0
473	GOLD and the fixed ratio. International Journal of COPD, 2012, 7, 663.	0.9	0
474	Reply: Comorbidities and Chronic Obstructive Pulmonary Disease: Is There a Place for Lung Fibrosis?. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1368-1368.	2.5	0
475	Persistence of Depressive Symptoms in Patients With COPD: A 3-Year Longitudinal Follow-up Analysis of the ECLIPSE Study Cohort. Chest, 2014, 146, 33A.	0.4	0
476	Are patients with COPD treated with NIV in accordance with national guidelines? An internal audit. European Clinical Respiratory Journal, 2014, 1, 24506.	0.7	0
477	Overview of Safety of Fluticasone Furoate, Vilanterol, or Their Combination in COPD Patients With Moderate Airflow Obstruction: The Summit Trial. Chest, 2016, 150, 922A.	0.4	0
478	HIGH-SENSITIVITY CARDIAC TROPONIN I AND RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH COPD AND HEIGHTENED CARDIOVASCULAR RISK: A BIOMARKER SUB-STUDY OF THE SUMMIT TRIAL. Journal of the American College of Cardiology, 2017, 69, 1819.	1.2	0
479	Exposure Interaction: A Lifelong Phenomenon with Relevance to Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 947-948.	2.5	0
480	The TRINITY study: Twitter discussion from a respiratory journal club – Authors' reply. Lancet Respiratory Medicine, 2017, 5, e26.	5.2	0
481	Biomarkers to guide antibiotic therapy for COPD exacerbations. The Cochrane Library, 0, , .	1.5	0
482	Childhood Asthma, Lung Function Trajectories, and Chronic Obstructive Pulmonary Disease: An Additional Step Forward. Annals of the American Thoracic Society, 2018, 15, 1030-1031.	1.5	0
483	Transformations of practice in online exercise training for patients with COPD led by physiotherapists – a qualitative study. Disability and Rehabilitation, 2021, , 1-10.	0.9	0
484	The association between beta-blocker therapy and daytime sleepiness in obstructive sleep apnoea. Sleep and Biological Rhythms, 2021, 19, 399-408.	0.5	0
485	Corticosteroid Resistance in Smokers – A Substudy Analysis of the CORTICO-COP Randomised Controlled Trial. Journal of Clinical Medicine, 2021, 10, 2734.	1.0	0
486	Asthma and COPD versus phenotypic traits: Toward precision medicine in chronic airway disease. Respiratory Medicine, 2021, 186, 106529.	1.3	0

#	ARTICLE	IF	CITATIONS
487	Editorial: Risk Prediction in Smokers. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2020, 7, 297-299.	0.5	0
488	Impact of the UK lockdown on people at risk of COPD. ERJ Open Research, 2021, 7, 00358-2021.	1.1	0
489	Authors'™ reply. International Journal of COPD, 2013, 8, 381.	0.9	0